Glycologix Inc. is an emerging biotechnology company targeting locally delivered biopolymers for the protection of soft tissues. Multiple unmet medical conditions can be addressed by replenishment of naturally occurring proteoglycans. Our platform discovery engine enables the preparation of synthetic structural mimics of proteoglycans. Despite their high molecular weight, these novel materials are are highly soluble, enabling optimal tissue coverage. Focused indications for the platform include interstitial cystitis, dry eye, post-surgical adhesion prevention, osteoarthritis, spinal disk disease, and wound repair. Glycologix is supported in part by grants from the NIH.
Medimetrics is the pioneer and global leader in electronic oral drug delivery and is committed to innovating healthcare. Medimetrics has created the IntelliCap® system for precise delivery of drugs in the gastro-intestinal tract, the measurement and reporting of conditions in the body, and sampling of gut fluids for example in gut microbiome research. It is the world’s first and only smart oral electronic drug delivery system. Available as an R&D service the IntelliCap® system is a highly effective tool for targeted modified release formulation development. Available by license and co-development, the IntelliCap® technology is applied to create revolutionary new smart pharmaceutical products.
Medimetrics has locations in the Netherlands, USA, and Germany.
A Revolution in Mobile Diabetes System with Powerful Data Analytics. Diabetes care is in your hand! Please visit www.glucoguide.com for further information. You can also search “glucoguide” in App Store or Google Play Store to download and install.